A CRISPR/AI driven foundry for precision immune cell engineering
To accelerate the path to the clinic, Artisan’s revolutionary cell foundry creates custom-engineered cells for therapeutic applications. The foundry utilizes Artisan’s STAR platform, which builds upon our deep expertise in CRISPR-enabled multiplex cell engineering by combining a proprietary family of novel endonuclease editing systems with high-throughput workflows and data analysis.
This platform has been proven out across many relevant cell types including T cells, iPSC, primary cells, cancer cells, as well as with industrial cell lines like CHO or HEK293. Moreover, our platform reproducibly deliveries superior editing efficiencies (>90%) that enable entirely new cell therapy strategies for increasing efficacy and/or safety.
See the Difference
Current viral-based cell therapy platforms cannot capture the same amount of value because of their inability to identify and optimize high-value candidate cell therapy designs.
Artisan’s approach is either fully non-viral or can be combined with viral payload (CAR) delivery, providing solutions based on a more comprehensive understanding of how different cell therapy design strategies affect indicators of clinical performance in shortened timelines.
Artisan Cell Therapeutics
Viral Cell Therapeutics
How it Works
The foundry builds designer cells using a comprehensive and proprietary high-throughput screening workflow that scales from 1-10,000’s of edits, then tests lead candidates across a panel of genotypic and phenotypic assays, resulting in the identification and selection of the best cell therapy candidates for clinical development.
Our differentiation lies in our vision and approach to cell engineering, which is based on decades of solving complex cell engineering challenges through the generation of innovative technology platforms.